

INTRODUCTION

Upper gastrointestinal bleeding is defined as bleeding in the gastrointestinal proximal to the ligament of Treitz, and is categorized into variceal and non variceal bleeding (*Barkun et al., 2003*).

Upper gastrointestinal bleeding is the commonest emergency medical admission for gastroenterology worldwide and has a significant inpatient mortality rate of 10% (*Hearnshaw et al., 2011*).

Upper gastrointestinal bleeding worldwide occurs at a rate of approximately 40 – 150 cases per 100,000 per year (*Gralnek et al., 2015*), with more than 350,000 annual hospital admissions in Canada (*Longstreth et al., 1995*).

In Egypt the variceal bleeding is the commonest cause of UGIB as documented by various studies, 60.1% by *Abeid, (2006)*, 36% by *Bayoumi, (2009)* and 31% by *Gado et al. (2012)*.

Endoscopy plays a central role in the diagnosis and management of upper gastrointestinal bleeding; advances in endoscopic techniques have rendered endoscopy as the first line of diagnostic & therapeutic interventions for patients with upper gastrointestinal bleeding (*Kwan and Norton, 2007*).

Patients who continue in hemodynamic instability need urgent endoscopy, preferably in the intensive care

unit. All others can undergo endoscopy as soon as possible, hopefully within 24–48 h. The chance of missing a second bleeding lesion under a pool of blood is low for patients with acute upper gastrointestinal bleeding, but is not obviously zero, and thus all such patients should undergo repeat endoscopy in 24–48 hours (*Putchaet al., 1997*).

The mortality rate of acute upper gastrointestinal bleeding decreased slightly following the introduction of endoscopic intervention modalities in the 1980s and better care in high dependency bleeding units (*Putcha et al., 1973*). Rebleeding is considered the most important risk factor for mortality and occurs in 10-30% of those successfully treated (*Saeed et al., 1995*).

Common causes of acute upper gastrointestinal bleeding are as follows: Peptic ulcer disease, Esophageal or gastric varices, arteriovenous malformations, Mallory-Weiss tears, Tumors, Esophagitis and Dieulafoy's lesions (*Savides et al., 1996*).

Variceal bleeding treatments frequently include endoscopic banding or sclerotherapy of esophageal varices in parallel with splanchnic vasoconstrictors and intensive medical care (*Harry et al., 2002*). Alternative interventions include; decompressive surgical shunts and Transjugular Intrahepatic Portosystemic Shunts (TIPS) (*Zoli et al., 2005*).

Peptic ulcer due to the *Helicobacter pylori* and Non-Steroidal Anti-inflammatory Drugs (NSAIDs) is responsible for the majority of bleeding ulcers (*Bardou et al., 2003*). In patient with bleeding peptic ulcer and high risk stigma, endoscopic treatment is the best used approach (*Bardou et al., 2003*). It improves outcome of these patients significantly decreasing both recurrent bleeding and mortality (*Barkun et al., 2003*).

Endoscopy is of great importance in accurate diagnosis of the site of upper gastrointestinal bleeding whether variceal or from other gastrointestinal lesions (*Pagliari et al., 1995*).

AIM OF THE WORK

To measure the prognostic factors of patients presented by haematemesis to the Emergency Department of Ain Shams University Hospital over the period of six months, from January to June 2015.

LITERATURE REVIEW

Definition

Upper Gastrointestinal Bleeding:

Upper gastrointestinal bleeding (UGIB) is defined as bleeding in the gastrointestinal proximal to the ligament of Treitz, and is categorized into variceal and non variceal bleeding (*Barkun et al., 2003*).

Epidemiology:

UGIB is the commonest emergency medical admission for gastroenterology worldwide and has a significant inpatient mortality rate of 10% (*Hearnshaw et al., 2011*). It occurs at a rate of approximately 40-150 cases per 100,000 per year, worldwide (*Gralnek et al., 2015*), with more than 350,000 annual hospital admissions in Canada (*Longstreth et al., 1995*).

In Egypt the variceal bleeding is the commonest cause of UGIB as documented by various studies, 60.1% by *Abeid, (2006)*, 36% by *Bayoumi (2009)* and 31% by *Gado et al. (2012)*.

Endoscopy plays a central role in the diagnosis and management of UGIB; advances in endoscopic techniques have rendered endoscopy as the first line of diagnostic & therapeutic interventions for patients with UGIB (*Kwan et al., 2007*).

Upper endoscopy is required for most patients with UGIB and should be performed within 24 h of hospital admission after adequate prior fluid resuscitation (*Szura et al., 2015*).

Rebleeding in upper gastrointestinal bleeding occurs in 7%–16%, despite endoscopic therapy. Rebleeding is especially high in variceal bleeding and peptic ulcer bleeding (*Kumar and Sibia, 2015*). In cases of rebleeding, a second attempt at endoscopic therapy is recommended to reduce the need for surgery (*Szura et al., 2015*).

The mortality rate of acute UGIB decreased slightly following the introduction of endoscopic intervention modalities in the 1980s and better care in high dependency bleeding units (*Stollman et al., 1973*).

Causes & Pathophysiology

Upper gastrointestinal bleeding (UGIB) is a common medical condition that results in increased patient's morbidity and medical care costs. Vomiting of blood or coffee-ground like material (hematemesis) and/or melena (black, tarry stools) is the common presentation of this condition (*Jutabha and Jensen, 1996*).

Common causes of acute upper gastrointestinal bleeding are as follows: Peptic ulcer disease, Esophageal or gastric varices, arteriovenous malformations, Mallory-Weiss tears, Tumors, Esophagitis and Dieulafoy's lesions (*Loperfido et al, 2009; Gralnek et al, 2015*). Acute UGIB can be categorized into several broad categories as followed (Table 1) (*Jutabha and Jensen, 1996*):

"A prospective series of 1000 cases of severe upper gastrointestinal bleeding at the UCLA and West Los Angeles Veterans Administration Medical Centers published in 1996 found the following distribution of causes" (*Jutabha and Jensen, 1996*):

- Peptic ulcer disease — 55%
- Esophagogastric varices — 14%
- Arteriovenous malformations — 6%
- Mallory-Weiss tears — 5%
- Tumors and erosions — 4%
- Dieulafoy's lesion — 1%
- Other — 11%

Table (1): Etiology of acute UGIB.

Etiology of Acute Upper Gastrointestinal Bleeding	
Ulcerative or erosive Peptic ulcer disease Idiopathic Drug induced Aspirin Nonsteroidal antiinflammatory drugs Infectious Helicobacter pylori Cytomegalovirus Herpes simplex virus Stress-induced ulcer Zollinger Ellison Syndrome Esophagitis Peptic Infectious Candida albicans Herpes simplex virus Cytomegalovirus Miscellaneous Pill-induced Alendronate Tetracycline Quinine Potassium chloride Aspirin Nonsteroidal antiinflammatory drugs Portal hypertension Esophageal varices Gastric varices Duodenal varices Portal hypertensive gastropathy	Arterial, venous, or other vascular malformations Idiopathic angiomias Osler-Weber-Rendu syndrome Dieulafoy's lesion Watermelon stomach (gastric antral vascular ectasia) Radiation-induced telangiectasia Blue rubber bleb nevus syndrome Traumatic or post-surgical Mallory-Weiss tear Foreign body ingestion Post-surgical anastomosis Aortoenteric fistula Post gastric/duodenal polypectomy Tumors Benign Leiomyoma Lipoma Polyp (hyperplastic, adenomatous, hamartomatous) Malignant Adenocarcinoma Gastrointestinal stromal tumor Lymphoma Kaposi's sarcoma Carcinoid Melanoma Metastatic tumor Miscellaneous Hemobilia Hemosuccus pancreaticus

In Egypt, it was also showed that the most common causes of acute UGIB were oesophago-gastric varices (53.3%), erosions (41.7%) and ulcers (24.9%) (*Esmat et al., 2002*).

Gastroesophageal varices:

"The major blood supply to *esophageal varices* is the left gastric vein. The posterior branch drains into the azygos system, whereas the anterior branch communicates with varices just below the esophageal junction and forms a bundle of thin parallel veins that run in the junction area and continue in large tortuous veins in the lower esophagus". *Gastric varices* get their blood supply from the short gastric veins and drain into the deep esophageal intrinsic veins (*Kitano et al., 1986*).

In portal hypertension there is a hepatofugal (reversal) flow, leading to diversion of venous blood *uphill* in the cephalic direction, through the left gastric vein to the esophageal venous plexus. The resulting varices are highly eminent in the lower-to-mid thirds of the esophagus(*Cihangiroglu et al., 2001*). *Downhill varices* are due to Superior Vena Cava (SVC) obstruction(*Cihangiroglu et al., 2001*).

"*Gastroesophageal variceal hemorrhage*, a major complication of portal hypertension resulting from cirrhosis, occurs in 25-35% of patients with cirrhosis and accounts for 80-90% of bleeding episodes in these patients"(*Groszmann et al., 1990*).

Variceal bleeding is associated with more substantial morbidity and mortality than others & with higher hospital costs (*Gralnek et al., 1999*).




Fig. (1A): Oesophageal varices (*Makhlouf, MA*)

"Up to 30% of initial bleeding episodes are fatal and as many as 70% of survivors have recurrent bleeding after a first variceal hemorrhage" (*Northern Italian Endoscopic Club, 1988*). Moreover, the one-year survival rate of patients after variceal bleeding can be poor (32-80%) (*Graham and Smith, 1981*).

The most common cause of portal hypertension is liver cirrhosis (as a result of chronic liver disease) (*Rockey and Chung, 1998*). Most patients with liver cirrhosis develop portal hypertension due to increased intrahepatic resistance (presinusoidal, sinusoidal, and postsinusoidal locations) as well as increased flow through a hyperdynamic splanchnic system (*Rockey and Chung, 1998*).

Varices can be defined as portosystemic collaterals formed after dilatation of preexisting vascular channels by the effect of portal hypertension (*Graham and Smith, 1981*). The most common site of esophageal varices is the lower third of the esophagus (distal 3-5 cm) (*Graham and Smith, 1981*).

Gastroesophageal varices are present in 40%-60% of patients with cirrhosis; their presence and size are related to the underlying cause, duration, and severity of cirrhosis (*Gupta et al., 1998*).

The risk of developing varices parallels with the severity of liver disease as reflected by Child's grading. It is further suggested that platelet count also predicts the development of varices (*D'Amico et al., 2001*). However, the rate of development and progression of OV in patients with cirrhosis has not been extensively evaluated (*Merli et al., 2003*).

Despite the high prevalence of varices in patients with cirrhosis, bleeding only occurs in about one third of patients (*Groszmann et al., 1990*).

Endoscopic predictors of bleeding include large varices and endoscopic red signs (e.g., red wale markings) on the variceal wall (*Northern Italian Endoscopic Club, 1988*).

A combination of clinical and endoscopic findings including an advanced Child-Pugh class of cirrhosis (Table 2), large varices, and the presence of red wale markings

correlate highly with the risk of a first bleeding episode in patients with cirrhosis (*Northern Italian Endoscopic Club, 1988*).

The risk of bleeding from varices is correlated to the Child-Pugh's score, not just because of more severe portal hypertension, but also because it is related to other factors such as nutritional deficiency, coagulopathy, and increased fibrinolysis in advanced liver disease (*Cales et al., 1990*).

Furthermore, an association between bacterial infection and failure to control bleeding has been observed (*Cales et al., 1990*). And a diurnal periodicity of variceal bleeding has also been observed. Bleeding episodes occur more frequently in the early mornings and late evenings, probably as a result of hyperdynamic blood flow in the portal system after meals (*McCormick et al., 1995*).

Table (2): Scoring systems for quantifying the severity of cirrhosis. Severity of liver disease can be described using the Child–Pugh score or MELD score. The Child–Pugh score is the sum of severity scores for Child class, variceal size and red wale markings the variables shown below.

Category	1	2	3
Encephalopathy	0	I/II	III/IV
Ascites	Absent	Mild-moderate	Severe
Bilirubin (μmol/L)	<34	34–51	>51
Albumin (g/L)	>35	28–35	<28
INR	<1.3	1.3–1.5	>1.5

Child–Pugh class A represents a score of ≤ 6 , class B a score of 7–9, and class C, ≥ 10 .

The MELD score is a formula that includes three laboratory-based variables reflecting the severity of liver disease. It was originally used to predict the short-term mortality after placement of a transjugular intrahepatic portosystemic stent-shunt for variceal bleeding. Subsequently, it has been used in selecting candidates for liver transplantation. INR, international normalised ratio (*Tripathi et al., 2015*).

Several prognostic indices have been developed to predict which patients with esophageal varices are likely to bleed (*Northern Italian Endoscopic Club, 1988*). The most widely used index is still the North Italian Endoscopic Club index (NIEC index). This index is based on (1) severity of liver disease (Child–Pugh class), (2) size of varices, and (3) presence of red markings on the varices (*Northern Italian Endoscopic Club, 1988*).

Base on this index, cirrhotic patients have been classified into six risk classes, each with a prediction rate of bleeding (Table 3) (*Northern Italian Endoscopic Club, 1988*).

The NIEC index has been prospectively validated on independent series. Yet, with the best prognostic index, one could only predict less than 40% of variceal bleeding. Obviously, some factors predisposing to variceal bleeding remain to be discovered (*Northern Italian Endoscopic Club, 1988*).

Table (3): NICE index.

Risk class	NIEC Index	Rate of bleeding (%)		
		6 months	1 year	2 years
1	< 20.0	0.0	1.6	6.8
2	20.0–25.0	5.4	11.0	16.0
3	25.1–30.0	8.0	14.8	25.5
4	30.1–35.0	13.1	23.3	27.8
5	35.1–40.0	21.8	37.8	58.8
6	> 40.0	58.5	68.9	68.9

Variceal pressure may be measured accurately and relatively noninvasively with a pressure-sensitive endoscopic gauge (*Boschet et al., 1986*). It may be an important predictor for variceal hemorrhage (*Nevens et al., 1998*).

A commonly employed system of classification of OV includes the following (*Beppu et al., 1981*):

- F1: Small straight varices
- F2: Enlarged tortuous varices that occupy less than one-third of the lumen
- F3: Large coil-shaped varices that occupy more than one-third of the lumen

It is important to insufflate the esophagus while estimating variceal size; failure to do so leads to overestimation (*Beppu et al., 1981*).

Varices in the gastric fundus also bleed frequently. Gastric varices are often classified according to their location, which correlates with their risk of hemorrhage (*Sarin et al., 1992*):

- Varices in direct continuity with the esophagus along the lesser and greater curves of the stomach are called gastroesophageal varices (GOV) types 1 and 2 respectively.
- Isolated gastric varices in the fundus (IGV1) occur less frequently than GOVs (10% versus 90%).

Most variceal bleeding temporarily stops by the time the patient arrives at the hospital. Without proper treatment, however, recurrent bleeding occurs in 30–40% within the next 2–3 days, and up to 60% within 1 week (*Burroughset al., 1989*).

Two cohort studies have showed that after the index bleeding, mortality is highest in the first 5 days and returns to baseline levels by 3–4 months. This is the critical time window for optimal treatment to improve survival of variceal bleeders (*Burroughset al., 1989*).

The risk of early rebleeding is greatest in the first 48 hours after admission and declines subsequently (*Graham and Smith, 1981*).

Peptic ulcer disease:

The most common non-variceal bleeding etiologies include gastroduodenal peptic ulcer (20%-50%) (*Szura et al., 2015*).

Four major risk factors for bleeding peptic ulcers (*Hallaset al., 1995*):

- *Helicobacter pylori* infection

- Nonsteroidal antiinflammatory drugs (NSAIDs)
- Stress
- Gastric acid

Reduction or elimination of these risk factors reduces ulcer recurrence and rebleeding rates (*Bayerdorffer et al., 1995*).

H. pylori are spiral bacteria that infect the superficial gastric mucosa and appear to be transmitted by the fecal-oral route (Figure 1B)(*Nakamura et al., 1997*).



Figure (1B): Gastroenterological Society of Australia, GESA 2006

The bacterium generally does not invade gastroduodenal tissue. Instead, it renders the underlying mucosa more vulnerable to acid peptic damage by disrupting the mucous layer, liberating enzymes and toxins, and adhering to the gastric epithelium (*Nakamura et al., 1997*).

In addition, the host immune response to *H. pylori* incites an inflammatory reaction which further perpetuates tissue injury (*Nakamura et al., 1997*). The chronic